Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. Th...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2017-07, Vol.23 (26), p.4675-4688 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4688 |
|---|---|
| container_issue | 26 |
| container_start_page | 4675 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 23 |
| creator | Martini, Giulia Troiani, Teresa Cardone, Claudia Vitiello, Pietropaolo Sforza, Vincenzo Ciardiello, Davide Napolitano, Stefania Della Corte, Carminia Maria Morgillo, Floriana Raucci, Antonio Cuomo, Antonio Selvaggi, Francesco Ciardiello, Fortunato Martinelli, Erika |
| description | In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the
-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon. |
| doi_str_mv | 10.3748/wjg.v23.i26.4675 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5514633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1925511557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-b1e04ce614a3feeb131dadc061083e23228876dc250f7050dea99af1d2f1411c3</originalsourceid><addsrcrecordid>eNpVkUtLxDAUhYMoOj72riRLN615NH24EGTwBYIudB3uJLdjpW00SUf892ZwFF2dxT3n3AMfIcec5bIq6rOP12W-EjLvRJkXZaW2yEwI3mSiLtg2mXHGqqyRotoj-yG8MiakVGKX7Im6KlVZNzOiHz0GHCOF0dJ2ipNH6lo6YIQQIXaGGtc7jyZCTw2MBj2NHiEOKXROL6nHVYcf68yYJDlsZyEijeCXGMMh2WmhD3i00QPyfH31NL_N7h9u7uaX95kpShGzBUdWGCx5AbJFXHDJLVjDSs5qiUIKUafJ1gjF2oopZhGaBlpuRcsLzo08IBffvW_TYkBr0joPvX7z3QD-Uzvo9P_L2L3opVtppXhRSpkKTjcF3r1PGKIeumCw72FENwXNG5GsXKkqWdm31XgXgsf29w1nes1FJy46cdGJi15zSZGTv_N-Az8g5BdXj4zD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925511557</pqid></control><display><type>article</type><title>Present and future of metastatic colorectal cancer treatment: A review of new candidate targets</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Martini, Giulia ; Troiani, Teresa ; Cardone, Claudia ; Vitiello, Pietropaolo ; Sforza, Vincenzo ; Ciardiello, Davide ; Napolitano, Stefania ; Della Corte, Carminia Maria ; Morgillo, Floriana ; Raucci, Antonio ; Cuomo, Antonio ; Selvaggi, Francesco ; Ciardiello, Fortunato ; Martinelli, Erika</creator><creatorcontrib>Martini, Giulia ; Troiani, Teresa ; Cardone, Claudia ; Vitiello, Pietropaolo ; Sforza, Vincenzo ; Ciardiello, Davide ; Napolitano, Stefania ; Della Corte, Carminia Maria ; Morgillo, Floriana ; Raucci, Antonio ; Cuomo, Antonio ; Selvaggi, Francesco ; Ciardiello, Fortunato ; Martinelli, Erika</creatorcontrib><description>In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the
-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v23.i26.4675</identifier><identifier>PMID: 28765689</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Chemotherapy, Adjuvant ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - metabolism ; Humans ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Precision Medicine ; Review</subject><ispartof>World journal of gastroenterology : WJG, 2017-07, Vol.23 (26), p.4675-4688</ispartof><rights>The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-b1e04ce614a3feeb131dadc061083e23228876dc250f7050dea99af1d2f1411c3</citedby><cites>FETCH-LOGICAL-c462t-b1e04ce614a3feeb131dadc061083e23228876dc250f7050dea99af1d2f1411c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514633/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514633/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28765689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martini, Giulia</creatorcontrib><creatorcontrib>Troiani, Teresa</creatorcontrib><creatorcontrib>Cardone, Claudia</creatorcontrib><creatorcontrib>Vitiello, Pietropaolo</creatorcontrib><creatorcontrib>Sforza, Vincenzo</creatorcontrib><creatorcontrib>Ciardiello, Davide</creatorcontrib><creatorcontrib>Napolitano, Stefania</creatorcontrib><creatorcontrib>Della Corte, Carminia Maria</creatorcontrib><creatorcontrib>Morgillo, Floriana</creatorcontrib><creatorcontrib>Raucci, Antonio</creatorcontrib><creatorcontrib>Cuomo, Antonio</creatorcontrib><creatorcontrib>Selvaggi, Francesco</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Martinelli, Erika</creatorcontrib><title>Present and future of metastatic colorectal cancer treatment: A review of new candidate targets</title><title>World journal of gastroenterology : WJG</title><addtitle>World J Gastroenterol</addtitle><description>In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the
-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Metastasis</subject><subject>Precision Medicine</subject><subject>Review</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtLxDAUhYMoOj72riRLN615NH24EGTwBYIudB3uJLdjpW00SUf892ZwFF2dxT3n3AMfIcec5bIq6rOP12W-EjLvRJkXZaW2yEwI3mSiLtg2mXHGqqyRotoj-yG8MiakVGKX7Im6KlVZNzOiHz0GHCOF0dJ2ipNH6lo6YIQQIXaGGtc7jyZCTw2MBj2NHiEOKXROL6nHVYcf68yYJDlsZyEijeCXGMMh2WmhD3i00QPyfH31NL_N7h9u7uaX95kpShGzBUdWGCx5AbJFXHDJLVjDSs5qiUIKUafJ1gjF2oopZhGaBlpuRcsLzo08IBffvW_TYkBr0joPvX7z3QD-Uzvo9P_L2L3opVtppXhRSpkKTjcF3r1PGKIeumCw72FENwXNG5GsXKkqWdm31XgXgsf29w1nes1FJy46cdGJi15zSZGTv_N-Az8g5BdXj4zD</recordid><startdate>20170714</startdate><enddate>20170714</enddate><creator>Martini, Giulia</creator><creator>Troiani, Teresa</creator><creator>Cardone, Claudia</creator><creator>Vitiello, Pietropaolo</creator><creator>Sforza, Vincenzo</creator><creator>Ciardiello, Davide</creator><creator>Napolitano, Stefania</creator><creator>Della Corte, Carminia Maria</creator><creator>Morgillo, Floriana</creator><creator>Raucci, Antonio</creator><creator>Cuomo, Antonio</creator><creator>Selvaggi, Francesco</creator><creator>Ciardiello, Fortunato</creator><creator>Martinelli, Erika</creator><general>Baishideng Publishing Group Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170714</creationdate><title>Present and future of metastatic colorectal cancer treatment: A review of new candidate targets</title><author>Martini, Giulia ; Troiani, Teresa ; Cardone, Claudia ; Vitiello, Pietropaolo ; Sforza, Vincenzo ; Ciardiello, Davide ; Napolitano, Stefania ; Della Corte, Carminia Maria ; Morgillo, Floriana ; Raucci, Antonio ; Cuomo, Antonio ; Selvaggi, Francesco ; Ciardiello, Fortunato ; Martinelli, Erika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-b1e04ce614a3feeb131dadc061083e23228876dc250f7050dea99af1d2f1411c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Metastasis</topic><topic>Precision Medicine</topic><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Martini, Giulia</creatorcontrib><creatorcontrib>Troiani, Teresa</creatorcontrib><creatorcontrib>Cardone, Claudia</creatorcontrib><creatorcontrib>Vitiello, Pietropaolo</creatorcontrib><creatorcontrib>Sforza, Vincenzo</creatorcontrib><creatorcontrib>Ciardiello, Davide</creatorcontrib><creatorcontrib>Napolitano, Stefania</creatorcontrib><creatorcontrib>Della Corte, Carminia Maria</creatorcontrib><creatorcontrib>Morgillo, Floriana</creatorcontrib><creatorcontrib>Raucci, Antonio</creatorcontrib><creatorcontrib>Cuomo, Antonio</creatorcontrib><creatorcontrib>Selvaggi, Francesco</creatorcontrib><creatorcontrib>Ciardiello, Fortunato</creatorcontrib><creatorcontrib>Martinelli, Erika</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martini, Giulia</au><au>Troiani, Teresa</au><au>Cardone, Claudia</au><au>Vitiello, Pietropaolo</au><au>Sforza, Vincenzo</au><au>Ciardiello, Davide</au><au>Napolitano, Stefania</au><au>Della Corte, Carminia Maria</au><au>Morgillo, Floriana</au><au>Raucci, Antonio</au><au>Cuomo, Antonio</au><au>Selvaggi, Francesco</au><au>Ciardiello, Fortunato</au><au>Martinelli, Erika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Present and future of metastatic colorectal cancer treatment: A review of new candidate targets</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World J Gastroenterol</addtitle><date>2017-07-14</date><risdate>2017</risdate><volume>23</volume><issue>26</issue><spage>4675</spage><epage>4688</epage><pages>4675-4688</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the
-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>28765689</pmid><doi>10.3748/wjg.v23.i26.4675</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2017-07, Vol.23 (26), p.4675-4688 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5514633 |
| source | MEDLINE; Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Chemotherapy, Adjuvant Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Humans Molecular Targeted Therapy Neoplasm Metastasis Precision Medicine Review |
| title | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T13%3A33%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Present%20and%20future%20of%20metastatic%20colorectal%20cancer%20treatment:%20A%20review%20of%20new%20candidate%20targets&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Martini,%20Giulia&rft.date=2017-07-14&rft.volume=23&rft.issue=26&rft.spage=4675&rft.epage=4688&rft.pages=4675-4688&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v23.i26.4675&rft_dat=%3Cproquest_pubme%3E1925511557%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925511557&rft_id=info:pmid/28765689&rfr_iscdi=true |